Business ❯ Pharmaceuticals

Market Competition

Obesity Drugs Novo Nordisk Eli Lilly Obesity Treatments Weight Loss Medications Weight Loss Drugs Rivalry Bidding Wars Industry Trends Job Cuts Workforce Management Mergers and Acquisitions Weight Loss Sales Performance Regulatory Issues Product Development Pricing Pharmacy Benefit Managers Revenue Eli Lilly and Novo Nordisk GSK Market Dominance Pricing Strategies Johnson & Johnson Generic Drugs Biosimilars Industry Players Financial Performance Corporate Restructuring

FDA Expands GSK’s Arexvy to High-Risk Adults 18–49, Completing Trio of RSV Vaccines for Younger At‑Risk Group

U.S. vaccine advisers have not yet recommended immunization for this population.

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

House Panel Presses PBMs, Demands Details on Trump ‘Most Favored Nation’ Drug Deals

Novo Nordisk Foundation Installs Lars Rebien Sørensen as Chair After Shareholder Vote

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet